Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. (ELTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ELTX · as of Sep 30, 2025
Ownership Breakdown
32
Institutional Holders
▲ 9 vs Q2
$21.07M
Total Inst. Value
▲ $9.88M vs Q2
19.09M
Shares Outstanding
freeFloat 46.60%
1.94M
13F Shares Held
▲ 492,457 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ELTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
KNOLL CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 630.9K | 3.93% | 3.93% | $6.90B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 473.9K | 2.95% | 2.95% | $5.18B | Nov 7, 2025 | ▲ 19.2K |
BALYASNY ASSET MANAGEMENT L.P. pharmaceutical preparations | 148.1K | 92.21% | 92.21% | $1.62B | Nov 14, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 129.7K | 80.75% | 80.75% | $1.42B | Nov 12, 2025 | ▲ 8.9K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 120.2K | 74.85% | 74.85% | $1.32B | Nov 14, 2025 | ▲ 103.2K |
CAPTION MANAGEMENT, LLC pharmaceutical preparations | 105.0K | 65.38% | 65.38% | $1.15B | Nov 14, 2025 | — held |
MARSHALL WACE, LLP pharmaceutical preparations | 86.5K | 53.88% | 53.88% | $946.67M | Nov 13, 2025 | NEW |
NORTHERN TRUST CORP pharmaceutical preparations | 53.6K | 33.37% | 33.37% | $586.21M | Nov 14, 2025 | ▲ 2.6K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 48.7K | 30.31% | 30.31% | $532.46M | Nov 13, 2025 | NEW |
BLACKROCK, INC. pharmaceutical preparations | 44.2K | 27.52% | 27.52% | $483.49M | Nov 12, 2025 | ▲ 638 |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
10
Increased
+178.5K shares11
New Positions
first time holders2
Decreased
−19.0K shares3
Sold Out
fully exitedNet shares change (top 50)
+159.5K
+178.5K / −19.0K
Net new holders
+16
11 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ELTX insider trading · insider activity
Source: SEC Form 4
8
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Connelly Robert CEO, President and Director | Feb 2, 2026 | Award | 147,200 | $8.10 | $1.19M | 147.2K | Form 4 ↗ |
Connelly Robert CEO, President and Director | Feb 2, 2026 | Award | 73,600 | — | — | 120.6K | Form 4 ↗ |
Shah Preetam See Remarks | Feb 2, 2026 | Award | 47,900 | $8.10 | $388.0K | 47.9K | Form 4 ↗ |
Shah Preetam See Remarks | Feb 2, 2026 | Award | 24,000 | — | — | 24.0K | Form 4 ↗ |
DeMuth Peter Chief Scientific Officer | Feb 2, 2026 | Award | 41,600 | $8.10 | $337.0K | 41.6K | Form 4 ↗ |
DeMuth Peter Chief Scientific Officer | Feb 2, 2026 | Award | 20,800 | — | — | 21.5K | Form 4 ↗ |
Haqq Christopher See Remarks | Feb 2, 2026 | Award | 25,400 | — | — | 57.4K | Form 4 ↗ |
Haqq Christopher See Remarks | Feb 2, 2026 | Award | 50,900 | $8.10 | $412.3K | 50.9K | Form 4 ↗ |
Chudnovsky Yekaterina
| Jun 3, 2025 | Award | 103,225 | $7.75 | $800.0K | 103.2K | Form 4 ↗ |
Ashe Carol Gail director | May 19, 2025 | Award | 7,900 | $5.84 | $46.1K | 7.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Elicio Therapeutics, Inc. (ELTX) is primarily owned by institutional investors, who hold approximately 10.2% of total shares outstanding. Company insiders own approximately 53.40%, while retail and public investors account for the remaining 36.41%.
The largest institutional shareholder of Elicio Therapeutics, Inc. is KNOLL CAPITAL MANAGEMENT, LLC, holding approximately 630,915 shares — equal to 3.93% of outstanding shares — as of September 30, 2025.
A total of 32 institutional investors currently hold ELTX stock, with a combined institutional value of approximately $21,070,319 as of the most recent 13F filing period.
Frequently asked questions
ELTX ownershipElicio Therapeutics, Inc. (ELTX) is primarily owned by institutional investors, who hold approximately 10.2% of shares. The largest shareholder is KNOLL CAPITAL MANAGEMENT, LLC with a 3.93% stake. Company insiders hold 53.40%. Data sourced from SEC Form 13F as of September 30, 2025.